کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2796053 1155360 2006 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Anti-TNF-alpha therapy in ankylosing spondylitis
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی علوم غدد
پیش نمایش صفحه اول مقاله
Anti-TNF-alpha therapy in ankylosing spondylitis
چکیده انگلیسی

Ankylosing spondylitis (AS) is the prototype disease within the spondyloarthropathies (SpA), a group of diseases presenting mainly with spondylitis, pauci-articular peripheral arthritis and enthesiopathy. Non-steroidal anti-inflammatory drugs (NSAID) are the classical cornerstone of medical therapy in these patients; no real disease modifying antirheumatic treatment was available, until recently. TNF-alpha blocking agents (monoclonal antibodies or soluble receptors) are the first representative drugs, of which the indication has recently been expanded to encompass also patients with AS. Here, we review the data on clinical efficacy and safety, with focus on the compounds infliximab and etanercept. Publication of trial results with adalimumab is still under way; the efficacy of this compound in AS seems comparable with the other two agents.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cytokine - Volume 33, Issue 5, 7 March 2006, Pages 294–298
نویسندگان
, , ,